Evidence map›Paper›PMID 35681730›Full record

ArticleCancers2022

Targeting Immunosuppressive Tumor-Associated Macrophages Using Innate T Cells for Enhanced Antitumor Reactivity.

Yan-Ruide Li, James Brown, Yanqi Yu, Derek Lee, Kuangyi Zhou, Zachary Spencer Dunn, Ryan Hon, Matthew Wilson, Adam Kramer, Yichen Zhu and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Dichotomous role of CD47-SIRPActa pharmaceutica Sinica. B · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Yan-Ruide LiDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0002-9858-300X
James BrownDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0003-2013-1609
Yanqi YuDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Derek LeeDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Kuangyi ZhouDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Zachary Spencer DunnDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0003-2500-6006
Ryan HonDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Matthew WilsonDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Adam KramerDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0001-7818-3837
Yichen ZhuDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Ying FangDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Lili YangDepartment of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
University of California, Los Angeles · USUniversity of Southern California · US

Funding

California Institute for Regenerative Medicine TRAN1-12250University of California, Los Angeles Ablon Scholars AwardUniversity of California, Los Angeles UCLA BSCRC Innovation Award
6 · The paper itself

Abstract

The field of T cell-based and chimeric antigen receptor (CAR)-engineered T (CAR-T) cell-based antitumor immunotherapy has seen substantial developments in the past decade; however, considerable issues, such as graft-versus-host disease (GvHD) and tumor-associated immunosuppression, have proven to be substantial roadblocks to widespread adoption and implementation. Recent developments in innate immune cell-based CAR therapy have opened several doors for the expansion of this therapy, especially as it relates to allogeneic cell sources and solid tumor infiltration. This study establishes in vitro killing assays to examine the TAM-targeting efficacy of MAIT, iNKT, and γδT cells. This study also assesses the antitumor ability of CAR-engineered innate T cells, evaluating their potential adoption for clinical therapies. The in vitro trials presented in this study demonstrate the considerable TAM-killing abilities of all three innate T cell types, and confirm the enhanced antitumor abilities of CAR-engineered innate T cells. The tumor- and TAM-targeting capacity of these innate T cells suggest their potential for antitumor therapy that supplements cytotoxicity with remediation of tumor microenvironment (TME)-immunosuppression.

Indexed as

cancer immunotherapygamma delta T (γδT) cellsinnate T cellinvariant natural killer T (iNKT) cellmucosal-associated invariant T (MAIT) celltumor-associated macrophagetumor microenvironment (TME)

Identifiers

PMID35681730
PMCPMC9179365
OpenAlexW4281955040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.